Compare Deutsche Bank AG (DB) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Johnson & Johnson — how do they compare? Deutsche Bank AG trades at $38.22 (market cap $72.15B), while Johnson & Johnson trades at $259.81 (market cap $630.94B). The key difference: Johnson & Johnson is far larger — about 8.7× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.04%). Which is the better fit depends on your goals.
| DB | JNJ | |
|---|---|---|
Market Cap | $72.15B | $630.94B |
Sector | Financials | Health |
52-Week High | $40.33 | $267.24 |
52-Week Low | $28.37 | $172.78 |
Dividend Yield | 3.04% | 2.05% |
Volume | — | 6,156,228 |
Enterprise Value | — | $659.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $38.06, up 1.14% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with Q2 2026 revenue growth and a 10.02 P/E ratio trading below book value at 0.79. Recent developments include being named China's renminbi clearing bank and announcing a $500 million buyback. Net income margin improved to 22.04% in 2026, though Q2 earnings missed expectations.
DB presents a mixed investment case with attractive valuation metrics and strategic positioning in European banking, but faces execution risks from recent earnings miss and ongoing tax investigations. The stock trades at a discount to peers with moderate analyst support (21% buy rating) despite strong operational cash flow of $47.06 billion in 2025.
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
